Inhibitors of TGFβ and receptors have entered clinical trials (45–48). CAR-T cells expressing a dominant-negative TGF-βRII enhance T-cell expansion and prostate cancer eradication in clinical trials (49). The gene discussed is TGFB1; the disease is Familial prostate cancer.